A single immunization with covaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets

Journal of Virology

Volumn 84, Issue 16, 2010, Pages 7943-7952

  Bodewes, R ^a   Kreijtz, J H C M ^a   Van Amerongen, G ^a   Geelhoed Mieras, M M ^a,b   Verburgh, R J ^a   Heldens, J G M ^b   Bedwell, J ^c   Van Den Brand, J M A ^a   Kuiken, T ^a   Van Baalen, C A ^a,d   Fouchier, R A M ^a   Osterhaus, A D M E ^a,d   Rimmelzwaan, G F ^a,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Nobilon Schering Plough   (Netherlands)

^c BTG   (United Kingdom)

^d Viroclinics Biosciences BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COVACCINE HT; HEMAGGLUTININ; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; SUCROSE FATTY ACID SULPHATE ESTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELL CULTURE; CELL PROTECTION; CELLULAR IMMUNITY; FEMALE; FERRET; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLUENZA A (H5N1); INFLUENZA VACCINATION; NONHUMAN; PRIORITY JOURNAL; VIRUS DETECTION; VIRUS INACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BODY WEIGHT; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; FERRETS; FLOW CYTOMETRY; HEMAGGLUTINATION INHIBITION TESTS; HISTOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LUNG; MICROSCOPY; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; PHARYNX; VACCINATION; VACCINES, INACTIVATED;

AVES; INFLUENZA A VIRUS; MUSTELA; ORTHOMYXOVIRIDAE;

EID: 77954982419     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00549-10     Document Type: Article

References (47)

1. Baras, B., K. J. Stittelaar, J. H. Simon, R. J. Thoolen, S. P. Mossman, F. H. Pistoor, G. van Amerongen, M. A. Wettendorff, E. Hanon, and A. D. Osterhaus. 2008. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 3:e1401. (Pubitemid 351194015)
2. Bernstein, D. I., K. M. Edwards, C. L. Dekker, R. Belshe, H. K. Talbot, I. L. Graham, D. L. Noah, F. He, and H. Hill. 2008. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J. Infect. Dis. 197:667-675.
3. Bevan, M. J. 2006. Cross-priming. Nat. Immunol. 7:363-365.
4. Blom, A. G., and L. A. Hilgers. 2004. Sucrose fatty acid sulphate esters as novel vaccine adjuvants: effect of the chemical composition. Vaccine 23:743-754.
5. Bodewes, R., M. M. Geelhoed-Mieras, J. G. Heldens, J. Glover, B. N. Lambrecht, R. A. Fouchier, A. D. Osterhaus, and G. F. Rimmelzwaan. 2009. The novel adjuvant CoVaccineHT increases the immunogenicity of cell-culture derived influenza A/H5N1 vaccine and induces the maturation of murine and human dendritic cells in vitro. Vaccine 27:6833-6839.
6. Bodewes, R., G. F. Rimmelzwaan, and A. D. Osterhaus. Animal models for the preclinical evaluation of candidate influenza vaccines. Expert Rev. Vaccines 9:59-72.
7. Bresson, J. L., C. Perronne, O. Launay, C. Gerdil, M. Saville, J. Wood, K. Hoschler, and M. C. Zambon. 2006. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367:1657-1664. (Pubitemid 43744370)
8. CDC. 2009. Update: influenza activity - United States, April-August 2009. MMWR Morb. Mortal. Wkly. Rep. 58:1009-1012.
9. Claas, E. C., A. D. Osterhaus, R. van Beek, J. C. De Jong, G. F. Rimmelzwaan, D. A. Senne, S. Krauss, K. F. Shortridge, and R. G. Webster. 1998. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351:472-477.
10. de Jong, J. C., E. C. Claas, A. D. Osterhaus, R. G. Webster, and W. L. Lim. 1997. A pandemic warning? Nature 389:554.
11. Donaldson, L. J., P. D. Rutter, B. M. Ellis, F. E. Greaves, O. T. Mytton, R. G. Pebody, and I. E. Yardley. 2009. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ 339:b5213.
12. Frank, A. L., J. Puck, B. J. Hughes, and T. R. Cate. 1980. Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement. J. Clin. Microbiol. 12: 426-432.
13. Glansbeek, H. L., M. A. M. Bruijni, J. G. M. Heldens, L. A. T. Hilgers, and J. F. van den Bosch. 2008. Induction of protective immunity after a single vaccination with an inactivated cell culture derived influenza whole virus pandemic influenza vaccine adjuvanted with CoVaccine, p. 122-123. Abstr. 3rd Eur. Influenza Conf., Villamoura, Portugal.
14. Govorkova, E. A., J. E. Rehg, S. Krauss, H. L. Yen, Y. Guan, M. Peiris, T. D. Nguyen, T. H. Hanh, P. Puthavathana, H. T. Long, C. Buranathai, W. Lim, R. G. Webster, and E. Hoffmann. 2005. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J. Virol. 79:2191-2198. (Pubitemid 40204576)
15. Hampson, A. W. 2006. Ferrets and the challenges of H5N1 vaccine formulation. J. Infect. Dis. 194:143-145.
16. Hilgers, L. A., and A. G. Blom. 2006. Sucrose fatty acid sulphate esters as novel vaccine adjuvant. Vaccine 24(Suppl. 2):81-82.
17. Hoelscher, M., S. Gangappa, W. Zhong, L. Jayashankar, and S. Sambhara. 2008. Vaccines against epidemic and pandemic influenza. Expert Opin. Drug Deliv. 5:1139-1157.
18. Karber, G. 1931. Beitrag zur kollektiven behandlung pharmakologischer reihenversuche. Exp. Pathol. Pharmakol. 162:480-483.
19. Keitel, W. A., J. D. Campbell, J. J. Treanor, E. B. Walter, S. M. Patel, F. He, D. L. Noah, and H. Hill. 2008. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J. Infect. Dis. 198:1309-1316.
20. Kreijtz, J. H., Y. Suezer, G. de Mutsert, J. M. van den Brand, G. van Amerongen, B. S. Schnierle, T. Kuiken, R. A. Fouchier, J. Lower, A. D. Osterhaus, G. Sutter, and G. F. Rimmelzwaan. 2009. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J. Infect. Dis. 199:405-413.
21. Kreijtz, J. H., Y. Suezer, G. van Amerongen, G. de Mutsert, B. S. Schnierle, J. M. Wood, T. Kuiken, R. A. Fouchier, J. Lower, A. D. Osterhaus, G. Sutter, and G. F. Rimmelzwaan. 2007. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J. Infect. Dis. 195:1598-1606.
22. Lalor, P. A., R. J. Webby, J. Morrow, D. Rusalov, D. C. Kaslow, A. Rolland, and L. R. Smith. 2008. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J. Infect. Dis. 197:1643-1652.
23. Leroux-Roels, I., A. Borkowski, T. Vanwolleghem, M. Drame, F. Clement, E. Hons, J. M. Devaster, and G. Leroux-Roels. 2007. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370:580-589. (Pubitemid 47247854)
24. Lipatov, A. S., E. Hoffmann, R. Salomon, H. L. Yen, and R. G. Webster. 2006. Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/ 97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J. Infect. Dis. 194:1040-1043.
25. Mahmood, K., R. A. Bright, N. Mytle, D. M. Carter, C. J. Crevar, J. E. Achenbach, P. M. Heaton, T. M. Tumpey, and T. M. Ross. 2008. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26:5393-5399.
26. Middleton, D., S. Rockman, M. Pearse, I. Barr, S. Lowther, J. Klippel, D. Ryan, and L. Brown. 2009. Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. J. Virol. 83:7770-7778.
27. Nicholson, K. G., A. E. Colegate, A. Podda, I. Stephenson, J. Wood, E. Ypma, and M. C. Zambon. 2001. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357:1937-1943.
28. Ochi, A., A. Danesh, C. Seneviratne, D. Banner, M. E. Devries, T. Rowe, L. Xu, L. Ran, M. Czub, S. E. Bosinger, M. J. Cameron, C. M. Cameron, and D. J. Kelvin. 2008. Cloning, expression and immunoassay detection of ferret IFN-gamma. Dev. Comp. Immunol. 32:890-897.
29. Palmer, D., W. Dowle, M. Coleman, and G. Schild. 1975. Advanced laboratory techniques for influenza diagnosis: procedural guide, p. 25-62. U.S. Department of Health, Education and Welfare, Atlanta, GA.
30. Philippa, J., C. Baas, W. Beyer, T. Bestebroer, R. Fouchier, D. Smith, W. Schaftenaar, and A. Osterhaus. 2007. Vaccination against highly pathogenic avian influenza H5N1 virus in zoos using an adjuvanted inactivated H5N2 vaccine. Vaccine 25:3800-3808. (Pubitemid 46589756)
31. Presanis, A. M., D. De Angelis, T. New York City Swine Flu Investigation, A. Hagy, C. Reed, S. Riley, B. S. Cooper, L. Finelli, P. Biedrzycki, and M. Lipsitch. 2009. The severity of pandemic H1N1 influenza in the United States, from April to July 2009: a Bayesian analysis. PLoS Med. 6:e1000207.
32. Rimmelzwaan, G. F., M. Baars, E. C. Claas, and A. D. Osterhaus. 1998. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J. Virol. Methods. 74:57-66.
33. Rimmelzwaan, G. F., T. Kuiken, G. van Amerongen, T. M. Bestebroer, R. A. Fouchier, and A. D. Osterhaus. 2001. Pathogenesis of influenza A (H5N1) virus infection in a primate model. J. Virol. 75:6687-6691. (Pubitemid 32578188)
34. Rimmelzwaan, G. F., R. W. van der Heijden, E. Tijhaar, M. C. Poelen, J. Carlson, A. D. Osterhaus, and F. G. UytdeHaag. 1990. Establishment and characterization of canine parvovirus-specific murine CD4+ T cell clones and their use for the delineation of T cell epitopes. J. Gen. Virol. 71:1095-1102.
35. Rutigliano, J. A., P. C. Doherty, J. Franks, M. Y. Morris, C. Reynolds, and P. G. Thomas. 2008. Screening monoclonal antibodies for cross-reactivity in the ferret model of influenza infection. J. Immunol. Methods 336:71-77.
36. Stephenson, I., R. Bugarini, K. G. Nicholson, A. Podda, J. M. Wood, M. C. Zambon, and J. M. Katz. 2005. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 191:1210-1215.
37. Subbarao, K., A. Klimov, J. Katz, H. Regnery, W. Lim, H. Hall, M. Perdue, D. Swayne, C. Bender, J. Huang, M. Hemphill, T. Rowe, M. Shaw, X. Xu, K. Fukuda, and N. Cox. 1998. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279:393-396.
38. Treanor, J. J., J. D. Campbell, K. M. Zangwill, T. Rowe, and M. Wolff. 2006. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354:1343-1351.
39. Treanor, J. J., B. E. Wilkinson, F. Masseoud, J. Hu-Primmer, R. Battaglia, D. O'Brien, M. Wolff, G. Rabinovich, W. Blackwelder, and J. M. Katz. 2001. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19:1732-1737. (Pubitemid 32175735)
40. Turkstra, J. A., F. J. van der Meer, J. Knaap, P. J. Rottier, K. J. Teerds, B. Colenbrander, and R. H. Meloen. 2005. Effects of GnRH immunization in sexually mature pony stallions. Anim. Reprod Sci. 86:247-259.
41. Vajo, Z., J. Wood, L. Kosa, I. Szilvasy, G. Paragh, Z. Pauliny, K. Bartha, I. Visontay, A. Kis, and I. Jankovics. 2010. A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine development. J. Virol. 84:1237-1242.
42. Vesikari, T., N. Groth, A. Karvonen, A. Borkowski, and M. Pellegrini. 2009. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 27:6291-6295.
43. von Messling, V., D. Milosevic, and R. Cattaneo. 2004. Tropism illuminated: lymphocyte-based pathways blazed by lethal morbillivirus through the host immune system. Proc. Natl. Acad. Sci. U. S. A. 101:14216-14221.
44. WHO. 12 March 2010, accession date. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. http://www.who.int/csr/ disease/avian-influenza/country/cases-table-2010-03-04/en/index.html.
45. WHO. 12 March 2010, accession date. Pandemic (H1N1) 2009 - update 90. http://www.who.int/csr/don/2010-03-05/en/index.html.
46. Wood, J. M., G. C. Schild, R. W. Newman, and V. Seagroatt. 1977. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J. Biol. Stand. 5:237-247.
47. Zitzow, L. A., T. Rowe, T. Morken, W. J. Shieh, S. Zaki, and J. M. Katz. 2002. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J. Virol. 76: 4420-4429. (Pubitemid 34309579)